Delay in developing the market for Acofide
First written in FY2016. 16 of 21 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2024: 3 of 8 companies on the "Worse" side.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Although affected by a drug price revision, the functional dyspepsia treatment Acofide achieved market penetration and generated sales exceeding those of the previous fiscal year.」
For Acofide, which had previously been described as lagging in market development or having sales at approximately the previous year's level, market penetration advanced and sales exceeded those of the previous fiscal year. - FY2024In line with the prior-year periodAnnual report
「Sales of the functional dyspepsia treatment Acofide were approximately unchanged from the previous fiscal year.」
For Acofide, the company continued its previous market development measures, while stating that sales for the fiscal year were approximately unchanged from the previous fiscal year. - FY2023-Q3RestatedAnnual report
「The company is working to develop the markets for Acofide and Ferinject, focusing respectively on medical institutions that perform endoscopies and on the gastroenterology and obstetrics and gynecology fields.」
For Acofide, the company continues to develop the market, focusing on medical institutions that perform endoscopies. - FY2023-Q2RestatedAnnual report
「The company is working to develop the markets for Acofide and Ferinject, focusing respectively on medical institutions that perform endoscopies and on the gastroenterology and obstetrics and gynecology fields.」
For Acofide, the company continues to develop the market, focusing on medical institutions that perform endoscopies. - FY2023-Q1RestatedAnnual report
「The company is working to develop the markets for Acofide and Ferinject, focusing respectively on medical institutions that perform endoscopies and on gastroenterology and obstetrics and gynecology departments.」
The company continues to develop the market for Acofide, focusing on medical institutions that perform endoscopies, and for Ferinject, focusing on gastroenterology and obstetrics and gynecology departments. - FY2021-Q2WorsenedAnnual report
「The company continued to work mainly with medical institutions that perform endoscopies to identify potential patients with functional dyspepsia, but the product struggled due to the impact of people refraining from seeking medical care amid the spread of COVID-19.」
While continuing its response to the previous delay in market development, Acofide struggled as people refrained from seeking medical care amid the spread of COVID-19. - FY2020RestatedAnnual report
「The company is seeking progress for the functional dyspepsia treatment Acofide by working mainly with medical institutions that perform endoscopies to identify potential patients with functional dyspepsia.」
For Acofide, the company continues to identify potential patients, mainly through medical institutions that perform endoscopies. - FY2020-Q3RestatedAnnual report
「The company continues to work mainly with medical institutions that perform endoscopies to identify potential patients with functional dyspepsia.」
For Acofide, the company continues to identify potential patients, mainly through medical institutions that perform endoscopies. - FY2020-Q2RestatedAnnual report
「The company continues to work mainly with medical institutions that perform endoscopies to identify potential patients with functional dyspepsia.」
For Acofide, the company continues to identify potential patients, mainly through medical institutions that perform endoscopies. - FY2020-Q1RestatedAnnual report
「The company continues to work mainly with medical institutions that perform endoscopies to identify potential patients with functional dyspepsia.」
For Acofide, the company continues to identify potential patients, mainly through medical institutions that perform endoscopies. - FY2019RestatedAnnual report
「The company will continue working to raise awareness among medical institutions of the disease and its treatments, and develop Acofide into a core product in its prescription drug business.」
For Acofide, the company continues its efforts to develop the market by raising awareness at medical institutions. - FY2019-Q3RestatedAnnual report
「The company continues to work mainly with medical institutions that perform endoscopies to identify potential patients with functional dyspepsia.」
For Acofide, the company continues to identify potential patients, mainly through medical institutions that perform endoscopies. - FY2019-Q2RestatedAnnual report
「The company continues to work mainly with medical institutions that perform endoscopies to identify potential patients with functional dyspepsia.」
For Acofide, the company continues to identify patients, mainly through medical institutions that perform endoscopies, as a response to the delay in market development relative to plan. - FY2019-Q1RestatedAnnual report
「The company continues to work mainly with medical institutions that perform endoscopies to identify potential patients with functional dyspepsia.」
In response to the delay in Acofide's market development, the company continues to identify potential patients, mainly through medical institutions that perform endoscopies. - FY2018-Q2RestatedAnnual report
「In addition, although sales of the functional dyspepsia treatment Acofide increased, market development remained behind plan, and the company continues to work mainly with medical institutions that perform endoscopies to identify potential patients with functional dyspepsia.」
Acofide increased sales, while the delay in market development relative to plan and measures to identify patients, mainly through medical institutions that perform endoscopies, continued. - FY2018-Q1Response measures made more specificAnnual report
「Market development for the functional dyspepsia treatment Acofide is lagging behind plan, but the company is seeking progress by working mainly with medical institutions that perform endoscopies to identify potential patients with functional dyspepsia.」
The delay in market development relative to plan continues, while the company describes efforts to identify potential patients, mainly through medical institutions that perform endoscopies, as a countermeasure. - FY2017RestatedAnnual report
「Market development for Acofide is lagging behind plan, but the company is seeking progress by raising awareness among medical institutions of the disease, its treatments and related matters.」
The delay in Acofide's market development and measures to raise awareness at medical institutions are continuing. - FY2017-Q3RestatedAnnual report
「In addition, market development for the functional dyspepsia treatment Acofide is lagging behind plan, but the company is seeking progress by raising awareness among medical institutions of the disease, its treatments and related matters.」
The delay in Acofide's market development relative to plan and measures to raise awareness at medical institutions are continuing. - FY2017-Q2RestatedAnnual report
「Meanwhile, market development for the functional dyspepsia treatment Acofide is lagging behind plan, but the company is seeking progress by raising awareness among medical institutions of the disease, its treatments and related matters.」
The delay in Acofide's market development relative to plan and measures to raise awareness at medical institutions are continuing. - FY2017-Q1RestatedAnnual report
「Meanwhile, market development for the functional dyspepsia treatment Acofide is lagging behind plan, but the company is seeking progress by raising awareness among medical institutions of the disease, its treatments and related matters.」
The delay in Acofide's market development relative to plan and the response of raising awareness continue to be described. - FY2016MaterialisedAnnual report
「Market development for the functional dyspepsia treatment Acofide is lagging behind plan.」
The company also described measures to advance the product by raising awareness.